在早期中轴型脊柱关节炎中考虑时变处方偏倚评估首次换药后TNFi长期有效性:DESIR队列的逆概率加权分析
基于DESIR前瞻性观察队列708例早期中轴型脊柱关节炎初治患者、随访5年,采用边际结构模型(逆概率加权与迭代倾向评分)评估首次换用TNFi后的长期有效性。首次换药后达到ASAS40应答的风险比为2.4(95%CI 1.9至3.0),略低于初治患者首次TNFi的3.3(95%CI 2.9至3.8);HLA-B27阳性是首次换药后ASAS40应答的唯一独立相关因素。
要点
- 首次换用TNFi后ASAS40应答HR=2.4(95%CI 1.9至3.0),低于初治首次TNFi的HR=3.3(95%CI 2.9至3.8)。
- HLA-B27阳性是首次换药后ASAS40应答的唯一独立相关因素。
- 采用逆概率加权与迭代倾向评分校正时变处方偏倚后,首次换药应答幅度数值上较低但具有临床相关性。
核心结论
- 应用克服时变处方偏倚的创新方法后,首次换药后TNFi应答幅度较初治患者数值上较低但具有临床相关性。
研究设计与样本
- 观察性前瞻性队列(DEvenir des Spondylarthropathies Indifférenciées Récentes,DESIR),随访5年,纳入708例早期中轴型脊柱关节炎且未用过TNFi的患者。
- 采用边际结构模型(实施逆概率加权与迭代倾向评分)估计首次换药后TNFi的长期有效性,以治疗期间至少2次访视后的ASAS40应答为结局。
- 采用多因素Cox回归模型探索与结局相关的因素。
主要发现
- 首次换用TNFi后出现ASAS40应答的风险比为2.4(95%CI 1.9至3.0)。
- 该应答比略低于初治患者首次TNFi后的应答比3.3(95%CI 2.9至3.8)。
- HLA-B27阳性是首次换用TNFi后ASAS40应答的唯一独立相关因素。
关键数值与推荐
- 长期有效性结局定义为治疗期间至少2次访视后达到ASAS40应答。
- 首次换药后ASAS40应答HR=2.4(95%CI 1.9至3.0);初治首次TNFi后HR=3.3(95%CI 2.9至3.8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate long-term effectiveness of tumour necrosis factor inhibitor (TNFi) after a first switch, and their associated factors in an early axial spondyloarthritis (axSpA) population, considering time-varying prescription bias. METHODS: Observational prospective cohort (DEvenir des Spondylarthropathies Indifférenciées Récentes) with 5 years of follow-up, including 708 TNFi-naïve patients with early axSpA. Long-term effectiveness of TNFi after a first switch (ASAS40 response after at least 2 visits under treatment) were estimated using marginal structural models (implementing inverse-probability weighting and iterative propensity scores). Factors associated with the outcome were explored by multivariate Cox regression models. RESULTS: The hazard to present an ASAS40 response after a first TNFi switch was increased (HR=2.4 (95% CI 1.9 to 3.0)); this response ratio was slightly lower compared with the response in TNFi naïve patients after a first TNFi (HR=3.3 (95% CI 2.9 to 3.8)). HLA-B27 positive was the only factor independently associated with ASAS40 response after a first TNFi switch. CONCLUSION: After application of innovative methods to overcome time-varying prescription bias, the magnitude of the TNFi response after a first switch was found to be numerically lower but clinically relevant from the response in TNFi-naïve patients.
引用
- Pons M, Chevret S, Briot K, et al. Evaluation of long-term TNFi effectiveness after a first switch in early axial spondyloarthritis considering time-varying prescription bias: an inverse-probability weighting analysis of the DESIR cohort. RMD Open. 2022. PMID: 35042728. doi:10.1136/rmdopen-2021-001846
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。